Genprex (GNPX) said Monday that it has completed the phase 1 dose escalation portion of a trial of Reqorsa gene therapy in combination with Tecentriq to treat extensive stage small cell lung cancer.
The company also said the Safety Review Committee has approved initiating the phase 2 expansion part of the trial.
Shares of Genprex were down 7% in recent trading.
Price: 1.10, Change: -0.07, Percent Change: -5.60
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments